知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

242 records (took 0.039 seconds)

    High-throughput assay for virus entry and drug screening
    32.
    发明申请
    High-throughput assay for virus entry and drug screening 有权
    用于病毒进入和药物筛选的高通量测定

    公开(公告)号：US20050164171A1

    公开(公告)日：2005-07-28

    申请号：US11036568

    申请日：2005-01-14

    Applicant: Robert Davey ,  Andrey Kolokoltsov

    Inventor： Robert Davey ,  Andrey Kolokoltsov

    IPC: C07K14/15 ,  C12Q1/37 ,  C12Q1/66 ,  G01N33/569 ,  C12Q1/70 ,  C12N7/00

    CPC classification number: C07K14/005 ,  C07K2319/60 ,  C12N15/1044 ,  C12N2740/13043 ,  C12N2740/16322 ,  C12Q1/37 ,  C12Q1/66 ,  C12Q1/70 ,  G01N33/56983 ,  G01N2500/00 ,  Y10S435/975

    Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

    Abstract translation: 本发明提供快速病毒进入/结合检测测定。 将酶如萤光素酶并入HIV Nef蛋白的病毒包膜蛋白的C-末端，该蛋白将特异性地与细胞膜结合，以在病毒装配时将酶递送到病毒颗粒中。 然后可以通过测定感染细胞中的酶活性来测定病毒进入/结合。 该测定允许在病毒细胞接触后30分钟内高通量非放射性检测病毒进入。 该测定提供高的信噪比，并且可用于筛选影响病毒 - 细胞结合和进入的化合物。 该设计还允许将潜在的治疗性蛋白质包装到功能性病毒颗粒中并将其递送至特定的细胞靶标。

    Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains
    34.
    发明申请
    Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains 审中-公开
    具有c型凝集素样结构域的支架结构的蛋白质组合库

    公开(公告)号：US20040132094A1

    公开(公告)日：2004-07-08

    申请号：US10450472

    申请日：2003-06-13

    Inventor： Michael Etzerodt ,  Thor Las ,  Niels Jonas Heilskov Graversen ,  Hans Christian

    IPC: G01N033/53 ,  G01N033/543 ,  C07K009/00

    CPC classification number: C12N15/1044 ,  C07K14/4726 ,  C12N15/1034 ,  C40B40/08 ,  C40B50/06

    Abstract: A novel family of protein libraries comprising CTLDs (C-type Lectin-Like Domains) in which internal polypeptide loop-regions lining the ligand binding sites in CTLDs have been replaced with ensembles of completely or partially randomised polypeptide segments. Tetranectin CTLDs were chosen as framework for the preferred embodiment of the invention; and versatile phagemid vectors useful in the generation and manipulation of human and murine tetranectin CTLD libraries are disclosed as part of this invention. Tetranectin CTLDs in monomeric as well as in trimeric form are efficiently displayed as gene III fusions in fully functional form by the recombinant fd phage display vector. CTLD derivatives with affinity for new ligands may readily be isolated from libraries of vectors displaying CTLDs, in which loop-regions have been randomised, using one or more rounds of enrichment by screening or selection followed by amplification of the enriched subpopulation in each round. The efficiency with which protein products containing CTLDs with new binding properties can be produced, e.g. by bacterial expression and in vitro refolding, in mono-, tri-, or multimeric formats provides important advantages in terms of simplicity, cost and efficiency of generation, production and diagnostic or therapeutic applications in comparison to recombinant antibody derivatives.

    Abstract translation: 包含CTLD（C型凝集素样结构域）的蛋白质文库的新家族，其中在CTLD中配体结合位点衬里的内部多肽环区已被完全或部分随机化的多肽片段的整体替代。 选择Tetranectin CTLD作为本发明优选实施方案的框架; 并且用于生成和操纵人和鼠四联蛋白CTLD文库的多功能噬菌粒载体作为本发明的一部分被公开。 通过重组fd噬菌体展示载体，单体和三聚体形式的Tetranectin CTLD有效地显示为完全功能形式的基因III融合体。 对新配体具有亲和力的CTLD衍生物可以容易地从显示CTLD的载体文库中分离，其中环区已被随机化，使用一轮或多轮浓缩通过筛选或选择，随后在每轮中扩增富集的亚群。 可以生产含有具有新结合特性的CTLD的蛋白质产物的效率，例如， 通过细菌表达和体外重折叠，单 - ，三 - 或多聚体形式在与重组抗体衍生物相比的简单性，成本和生产效率，生产和诊断或治疗应用方面提供了重要的优点。

    Artificial antibody polypeptides
    36.
    发明授权
    Artificial antibody polypeptides 有权
    人工抗体多肽

    公开(公告)号：US06703199B1

    公开(公告)日：2004-03-09

    申请号：US09637614

    申请日：2000-08-11

    Applicant: Shohei Koide

    Inventor： Shohei Koide

    IPC: C12Q168

    CPC classification number: C07K14/78 ,  C07K16/00 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/565 ,  C07K2318/20 ,  C12N15/1037 ,  C12N15/1044 ,  C40B40/02 ,  G01N33/68 ,  G01N33/6845 ,  G01N33/78 ,  G01N2333/78

    Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.

    Abstract translation: 本发明提供了纤维连接蛋白III型（Fn3）多肽单体，编码所述单体的核酸分子和编码所述单体的杂化核酸文库。 还提供了制备Fn3多肽单体的方法和用于实施所述方法的试剂盒。 还提供了鉴定能够结合特异性结合配偶体（SBP）以形成多肽SSP复合物的多肽分子的氨基酸序列的方法，以及鉴定能够分解多肽分子的氨基酸序列的方法 以催化速率常数kcat和未催化速率常数kuncat催化化学反应，使得kcat / kuncat的比例大于10。

    Artificial antibody polypeptides
    37.
    发明授权
    Artificial antibody polypeptides 失效

    公开(公告)号：US06673901B2

    公开(公告)日：2004-01-06

    申请号：US09096749

    申请日：1998-06-12

    Applicant: Shohei Koide

    Inventor： Shohei Koide

    IPC: C07K1478

    CPC classification number: C07K14/78 ,  C07K16/00 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/565 ,  C07K2318/20 ,  C12N15/1037 ,  C12N15/1044 ,  C40B40/02 ,  G01N33/68 ,  G01N33/6845 ,  G01N33/78 ,  G01N2333/78

    Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.

    Artificial antibody polypeptides
    39.
    发明申请
    Artificial antibody polypeptides 有权
    人工抗体多肽

    公开(公告)号：US20030027319A1

    公开(公告)日：2003-02-06

    申请号：US09903412

    申请日：2001-07-11

    Inventor： Shohei Koide

    IPC: C12N009/64 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

    CPC classification number: C07K14/78 ,  C07K16/00 ,  C07K2317/565 ,  C12N15/1037 ,  C12N15/1044 ,  C40B30/04 ,  G01N33/6845

    Abstract: The present invention provides a fibronectin type III (Fn3) molecule, wherein the Fn3 contains a stabilizing mutation. The present invention also provides Fn3 polypeptide monobodies, nucleic acid molecules encoding monobodies, and variegated nucleic acid libraries encoding such monobodies. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform the methods.

    Abstract translation: 本发明提供了III型（Fn3）纤连蛋白，其中Fn3含有稳定突变。 本发明还提供Fn3多肽单体，编码单体的核酸分子，以及编码这种单体的杂化核酸文库。 还提供了制备Fn3多肽单体的方法和用于实施该方法的试剂盒。

Patent Agency Ranking